0.005%拉坦前列腺素與0.5%馬來酸噻嗎洛爾的固定合劑治療原發(fā)性開角型青光眼及高眼壓癥的降眼壓效果有效性的系統(tǒng)評(píng)價(jià)
發(fā)布時(shí)間：2018-07-20 19:26
【摘要】：目的：比較與評(píng)價(jià)FCLT與β-受體阻滯劑類對(duì)于POAG和OHT患者的降眼壓效果 方法：檢索了CENTRAL, MEDLINE, EMBASE,以及SCI。采用對(duì)照組為β-受體阻滯劑類降眼壓藥物,試驗(yàn)對(duì)象為POAG或OHT患者隨機(jī)對(duì)照試驗(yàn)或交叉試驗(yàn),使用MD作為結(jié)局指標(biāo)。 結(jié)果：共8個(gè)臨床試驗(yàn)符合標(biāo)準(zhǔn),納入受試對(duì)象1808人。FCLT每天使用一次與噻嗎洛爾相比可以更有效的降低日平均眼壓(MD-2.95[-3.34,-2.56], P0.00001)和24小時(shí)平均眼壓(MD-2.84[-3.57,-2.12], P0.00001)。而且可以減小眼壓波動(dòng)(MD-0.85[-1.18,-0.53],P0.00001)。 結(jié)論：FCLT用于POAG和OHT的患者,其降低日平均眼壓和24小時(shí)平均眼壓的效果更好,減小了眼壓的波動(dòng)。對(duì)于24小時(shí)眼壓的結(jié)果需要更多的高質(zhì)量隨機(jī)對(duì)照試驗(yàn)的進(jìn)一步證實(shí)。 目的：比較與評(píng)價(jià)FCLT與前列腺素類藥物對(duì)于POAG和OHT患者的降眼壓效果 方法：檢索了CENTRAL, MEDLINE, EMBASE,以及SCI。采用對(duì)照組為前列腺素類類降眼壓藥物,試驗(yàn)對(duì)象為POAG或OHT患者隨機(jī)對(duì)照試驗(yàn)或交叉試驗(yàn),使用MD作為結(jié)局指標(biāo)。 結(jié)果：共12個(gè)臨床試驗(yàn)符合標(biāo)準(zhǔn),納入受試對(duì)象2534人。FCLT與拉坦前列腺素相比可以更有效的降低日平均眼壓(MD-1.13[-1.47,-0.79], P0.00001),和24小時(shí)平均眼壓(MD-2.50[-3.58,-1.42], P0.00001)。而且可以減小眼壓波動(dòng)(MD-0.65[-1.02,-0.27],P=0.0007)。 FCLT與曲伏前列腺素相比在降低日平均眼壓方面沒有明顯差別(MD0.05[-0.19,0.29], P=0.68)。 FCLT與貝美前列腺素相比降24小時(shí)平均眼壓效果沒有明顯差異(MD0.20[-0.44,0.85], P=0.53)。 結(jié)論：FCLT用于POAG和OHT的患者,與拉坦前列腺素相比,其降低日平均眼壓和24小時(shí)平均眼壓的效果更好,減小了眼壓的波動(dòng)。與曲伏前列腺素和貝美前列腺素相比,降眼壓的效果沒有明顯差別。對(duì)于24小時(shí)眼壓的結(jié)果需要更多的高質(zhì)量隨機(jī)對(duì)照試驗(yàn)的進(jìn)一步證實(shí)。 目的：比較與評(píng)價(jià)FCLT與其成分藥物聯(lián)合應(yīng)用對(duì)于POAG和OHT患者的降眼壓效果 方法：檢索了CENTRAL, MEDLINE, EMBASE,以及SCI。采用對(duì)照組為0.005%拉坦前列腺素與0.5%馬來酸噻嗎洛爾聯(lián)合應(yīng)用,試驗(yàn)對(duì)象為POAG或OHT患者隨機(jī)對(duì)照試驗(yàn)或交叉試驗(yàn),使用MD作為結(jié)局指標(biāo)。 結(jié)果：共3個(gè)臨床試驗(yàn)符合標(biāo)準(zhǔn),納入受試對(duì)象961人。當(dāng)FCLT早上使用時(shí)日平均眼壓比其成分藥物聯(lián)合應(yīng)用高(MD1.10[0.81,1.39], P0.00001), FCLT晚上使用時(shí),平均眼壓沒有明顯差別(MD0.42[-0.06,0.89], P=0.09) 結(jié)論：對(duì)于POAG和OHT的患者,當(dāng)FCLT早上使用時(shí),與其成分藥物聯(lián)合應(yīng)用相比,其降低日平均眼壓的效果較差,當(dāng)FCLT晚上使用時(shí),它們降眼壓效果沒有明顯差別。 目的：比較與評(píng)價(jià)FCLT與其它前列腺素類與噻嗎洛爾的固定合劑對(duì)于POAG和OHT患者的降眼壓效果 方法：檢索了CENTRAL, MEDLINE, EMBASE,以及SCI。采用對(duì)照組為其它前列腺素類與噻嗎洛爾的固定合劑,試驗(yàn)對(duì)象為POAG或OHT患者隨機(jī)對(duì)照試驗(yàn)或交叉試驗(yàn),使用MD作為結(jié)局指標(biāo)。 結(jié)果：共5個(gè)臨床試驗(yàn)符合標(biāo)準(zhǔn),納入受試對(duì)象720人。FCLT與0.004%曲伏前列腺素/0.5%噻嗎洛爾的固定合劑(FCTT, the fixed combination of0.004%tranvoprost and0.5%timolol)比較,當(dāng)兩種藥物晚上使用時(shí),FCLT組的日平均眼壓較低(MD-1.84[-3.34,-0.34], P=0.02)。FCLT與0.03%貝美前列腺素和0.5%噻嗎洛爾的固定合劑(FCBiT, the fixed combination of0.03%bimatroprost and0.5%timolol)相比,日平均眼壓較高(MD0.78[0.50,1.06], P0.00001),白天的眼壓波動(dòng)較高(MD1.10[0.45,1.75]],P=0.0009) 結(jié)論：對(duì)于POAG和OHT的患者,FCLT對(duì)于日平均眼壓及眼壓波動(dòng)的控制不如FCBiT,對(duì)于日平均眼壓的控制優(yōu)于FCTT。需要高質(zhì)量的隨機(jī)對(duì)照研究來證實(shí)與FCTT,FCBiT相比日平均眼壓的情況,以及24小時(shí)平均眼壓的情況。 目的：比較與評(píng)價(jià)FCLT與其它固定合劑對(duì)于POAG和OHT患者的降眼壓效果 方法：檢索了CENTRAL, MEDLINE, EMBASE,以及SCI。采用對(duì)照組為其它類型的固定合劑,試驗(yàn)對(duì)象為POAG或OHT患者隨機(jī)對(duì)照試驗(yàn)或交叉試驗(yàn),使用MD作為結(jié)局指標(biāo)。 結(jié)果：共9個(gè)臨床試驗(yàn)符合標(biāo)準(zhǔn),納入受試對(duì)象732人。FCLT比2%多佐胺/0.5%噻嗎洛爾固定合劑(FCDT, the fixed combination of2%dorzolamide and0.5%timolol)降低平均眼壓效果更佳(MD-0.59[-0.91,-0.26] P=0.0004)。對(duì)于眼壓波動(dòng)的控制兩者無明顯差別(MD-0.25[-0.98,0.47] P=0.49)o FCLT與0.2%溴莫尼定/0.5%噻嗎洛爾固定合劑(FCBT, the fixed combination of0.2%brimonidine and0.5%timolol)降低日平均眼壓的效果無明顯差別(MD-0.50[-2.07,1.07] P=0.53)。 結(jié)論：對(duì)于POAG和OHT的患者,FCLT降低日平均眼壓的效果優(yōu)于FCDT。 FCLT控制眼壓波動(dòng)與FCDT無明顯差別,FCLT與FCBT降低日平均眼壓效果無明顯差別。仍需要高質(zhì)量的隨機(jī)對(duì)照眼壓進(jìn)一步證實(shí)它們對(duì)日平均眼壓以及24小時(shí)均眼壓的影響。
[Abstract]:Objective : To compare and evaluate the IOP - lowering effect in patients with POAG and OHT in patients with POAG and OHT .
Methods : The subjects were randomly controlled trial or cross test of POAG or OHT , and MD was used as the outcome measure .
Results : The average intraocular pressure ( MD - 2.95 % - 3.34 , - 2.56 mmol , P0.001 ) and 24 - hour mean intraocular pressure ( MD - 2.84 - 3.57 , - 2.12 , P - 0.001 ) could be more effective than that of tiotropium . but also can reduce the fluctuation of intraocular pressure ( MD - 0.85 - 1.18 , - 0.53 billion , P0.001 ) .
Conclusion : The results showed that patients with POAG and OHT decreased the daily average intraocular pressure and the average intraocular pressure in 24 hours , and decreased the fluctuation of intraocular pressure .
Objective : To compare and evaluate the IOP lowering effect in patients with POAG and OHT in patients with POAG and OHT .
Methods : CENTRAL , EMBASE , and SCI were retrieved . The control group was used as prostaglandin - like pressure - lowering drugs . The subjects were either POAG or OHT patients randomized controlled trial or crossover trial , and MD was used as the outcome measure .
Results : There were 12 clinical trials in compliance with the criteria and included 2534 subjects in the test subjects . The daily average intraocular pressure ( MD - 1.13 , - 1 . 47 , - 0.79 diopter , P0.001 ) and 24 - hour mean intraocular pressure ( MD - 2.50 - 3.58 , - 1.42 ug , P0.001 ) were more effective than that of latanoprost . Also , IOP fluctuations ( MD - 0.65 - 1.02 , - 0.27 sqm , P = 0.0007 ) can be reduced . There was no significant difference in the mean ocular pressure ( MD0.05 ~ - 0.19 , 0.29 mmol , P = 0.68 ) than that of TPV . There was no significant difference in mean intraocular pressure ( MD0.20 - 0.44 , 0.85 mmol , P = 0.53 ) compared with the 24 - hour mean IOP reduction compared with BU.S . prost .
Conclusion : The results showed that patients with POAG and OHT had better effects on average intraocular pressure and IOP after 24 hours than that of latanoprost . The results showed that the effect of IOP was not significantly different .
Objective : To compare and evaluate the effect of combined therapy with the combination of the components in the patients with POAG and OHT .
Methods : CENTRAL , EMBASE , and SCI were retrieved . The control group was used in combination with 0.005 % latanoprost and 0.5 % thiadiazole lol . The subjects were either POAG or OHT patients randomized controlled trial or crossover trial , and MD was used as the outcome measure .
Results : Three clinical trials met the criteria and were included in 961 subjects . The average intraocular pressure was higher than that of its components ( MD1 . 10 鹵 0.81 , 1 . 39 渭g , P 0 . 00001 ) . The mean intraocular pressure was not significantly different ( MD0.42 鹵 0.06 , 0.89 擄 , P = 0.09 ) .
Conclusion : For patients with POAG and OHT , the effect of decreasing daily average intraocular pressure is less than that of the combined application of the components in the patients with POAG and OHT .
Objective : To compare and evaluate the IOP - lowering effect of the fixed mixture of FCLs and other prostaglandin and thiadiazole in patients with POAG and OHT .
Methods : CENTRAL , EMBASE , and SCI were retrieved . The control group was used as the fixed mixture of other prostaglandin and thiadiazole , and the subjects were either POAG or OHT patients randomized controlled trial or crossover trial , and MD was used as the outcome measure .
Results : A total of 5 clinical trials met the criteria and were included in the 720 human subjects of the test subjects . Compared with the fixed combination of 0.004 % travoprost and0.5 % lol lol , the daily average intraocular pressure was lower ( MD - 1.84 mmol - 3.34 , - 0.34 mmol , P = 0.02 ) when the two drugs were used at night . The daily average intraocular pressure was higher ( MD0 . 78 鹵 0.50 , 1.06 渭m , P 0 . 00001 ) than that of the fixed combination of 0.03 % bimatroprost and0.5 % thilol ( MD0 . 78 鹵 0 . 50 , 1.06 渭m , P 0 . 00001 ) .
Conclusion : For patients with POAG and OHT , the control of daily average intraocular pressure and intraocular pressure fluctuation is not as good as FCBiT , and the control of daily average intraocular pressure is better than that of Fctt . A high quality randomized controlled study is required to confirm the average intraocular pressure as compared with Fctt , FCBiT , and the average intraocular pressure in 24 hours .
Objective : To compare and evaluate the IOP lowering effect in patients with POAG and OHT in patients with POAG and OHT .
Methods : CENTRAL , EMBASE , and SCI were retrieved . The control group was used as other types of fixatives . The subjects were either POAG or OHT patients randomized controlled trial or crossover trial , and MD was used as outcome measure .
Results : A total of nine clinical trials were in compliance with the criteria and included 732 subjects in the test subjects . The results were better ( MD - 0.59 , - 0.91 , - 0.26 , P = 0.0004 ) than the 2 % dozonamine / 0.5 % tiotropium bromide fixation mixture . There was no significant difference in the control of IOP fluctuations ( MD - 0.25 mmol - 0.98 , 0.47 P P = 0.49 ) o FTs vs . 0.2 % brimonnidine / 0.5 % thiatelol fixed mixture ( Fcbt , the fixed combination of 0.2 % brizol and0.5 % lol lol ) decreased daily average intraocular pressure ( MD - 0.50 , - 2.07 , 1.07 , P = 0.53 ) .
Conclusion : For patients with POAG and OHT , the effect of the daily average IOP reduction was better than that of FTs in patients with POAG and OHT . There was no significant difference in the ocular pressure fluctuation between FTs and FCD . There was no significant difference in the daily average IOP between the FTs and FCB.However , high - quality randomized controlled intraocular pressure was still needed to further confirm their effects on daily average intraocular pressure and 24 - hour intraocular pressure .
【學(xué)位授予單位】：華中科技大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2014
【分類號(hào)】：R775.2
[Abstract]:Objective : To compare and evaluate the IOP - lowering effect in patients with POAG and OHT in patients with POAG and OHT .
Methods : The subjects were randomly controlled trial or cross test of POAG or OHT , and MD was used as the outcome measure .
Results : The average intraocular pressure ( MD - 2.95 % - 3.34 , - 2.56 mmol , P0.001 ) and 24 - hour mean intraocular pressure ( MD - 2.84 - 3.57 , - 2.12 , P - 0.001 ) could be more effective than that of tiotropium . but also can reduce the fluctuation of intraocular pressure ( MD - 0.85 - 1.18 , - 0.53 billion , P0.001 ) .
Conclusion : The results showed that patients with POAG and OHT decreased the daily average intraocular pressure and the average intraocular pressure in 24 hours , and decreased the fluctuation of intraocular pressure .
Objective : To compare and evaluate the IOP lowering effect in patients with POAG and OHT in patients with POAG and OHT .
Methods : CENTRAL , EMBASE , and SCI were retrieved . The control group was used as prostaglandin - like pressure - lowering drugs . The subjects were either POAG or OHT patients randomized controlled trial or crossover trial , and MD was used as the outcome measure .
Results : There were 12 clinical trials in compliance with the criteria and included 2534 subjects in the test subjects . The daily average intraocular pressure ( MD - 1.13 , - 1 . 47 , - 0.79 diopter , P0.001 ) and 24 - hour mean intraocular pressure ( MD - 2.50 - 3.58 , - 1.42 ug , P0.001 ) were more effective than that of latanoprost . Also , IOP fluctuations ( MD - 0.65 - 1.02 , - 0.27 sqm , P = 0.0007 ) can be reduced . There was no significant difference in the mean ocular pressure ( MD0.05 ~ - 0.19 , 0.29 mmol , P = 0.68 ) than that of TPV . There was no significant difference in mean intraocular pressure ( MD0.20 - 0.44 , 0.85 mmol , P = 0.53 ) compared with the 24 - hour mean IOP reduction compared with BU.S . prost .
Conclusion : The results showed that patients with POAG and OHT had better effects on average intraocular pressure and IOP after 24 hours than that of latanoprost . The results showed that the effect of IOP was not significantly different .
Objective : To compare and evaluate the effect of combined therapy with the combination of the components in the patients with POAG and OHT .
Methods : CENTRAL , EMBASE , and SCI were retrieved . The control group was used in combination with 0.005 % latanoprost and 0.5 % thiadiazole lol . The subjects were either POAG or OHT patients randomized controlled trial or crossover trial , and MD was used as the outcome measure .
Results : Three clinical trials met the criteria and were included in 961 subjects . The average intraocular pressure was higher than that of its components ( MD1 . 10 鹵 0.81 , 1 . 39 渭g , P 0 . 00001 ) . The mean intraocular pressure was not significantly different ( MD0.42 鹵 0.06 , 0.89 擄 , P = 0.09 ) .
Conclusion : For patients with POAG and OHT , the effect of decreasing daily average intraocular pressure is less than that of the combined application of the components in the patients with POAG and OHT .
Objective : To compare and evaluate the IOP - lowering effect of the fixed mixture of FCLs and other prostaglandin and thiadiazole in patients with POAG and OHT .
Methods : CENTRAL , EMBASE , and SCI were retrieved . The control group was used as the fixed mixture of other prostaglandin and thiadiazole , and the subjects were either POAG or OHT patients randomized controlled trial or crossover trial , and MD was used as the outcome measure .
Results : A total of 5 clinical trials met the criteria and were included in the 720 human subjects of the test subjects . Compared with the fixed combination of 0.004 % travoprost and0.5 % lol lol , the daily average intraocular pressure was lower ( MD - 1.84 mmol - 3.34 , - 0.34 mmol , P = 0.02 ) when the two drugs were used at night . The daily average intraocular pressure was higher ( MD0 . 78 鹵 0.50 , 1.06 渭m , P 0 . 00001 ) than that of the fixed combination of 0.03 % bimatroprost and0.5 % thilol ( MD0 . 78 鹵 0 . 50 , 1.06 渭m , P 0 . 00001 ) .
Conclusion : For patients with POAG and OHT , the control of daily average intraocular pressure and intraocular pressure fluctuation is not as good as FCBiT , and the control of daily average intraocular pressure is better than that of Fctt . A high quality randomized controlled study is required to confirm the average intraocular pressure as compared with Fctt , FCBiT , and the average intraocular pressure in 24 hours .
Objective : To compare and evaluate the IOP lowering effect in patients with POAG and OHT in patients with POAG and OHT .
Methods : CENTRAL , EMBASE , and SCI were retrieved . The control group was used as other types of fixatives . The subjects were either POAG or OHT patients randomized controlled trial or crossover trial , and MD was used as outcome measure .
Results : A total of nine clinical trials were in compliance with the criteria and included 732 subjects in the test subjects . The results were better ( MD - 0.59 , - 0.91 , - 0.26 , P = 0.0004 ) than the 2 % dozonamine / 0.5 % tiotropium bromide fixation mixture . There was no significant difference in the control of IOP fluctuations ( MD - 0.25 mmol - 0.98 , 0.47 P P = 0.49 ) o FTs vs . 0.2 % brimonnidine / 0.5 % thiatelol fixed mixture ( Fcbt , the fixed combination of 0.2 % brizol and0.5 % lol lol ) decreased daily average intraocular pressure ( MD - 0.50 , - 2.07 , 1.07 , P = 0.53 ) .
Conclusion : For patients with POAG and OHT , the effect of the daily average IOP reduction was better than that of FTs in patients with POAG and OHT . There was no significant difference in the ocular pressure fluctuation between FTs and FCD . There was no significant difference in the daily average IOP between the FTs and FCB.However , high - quality randomized controlled intraocular pressure was still needed to further confirm their effects on daily average intraocular pressure and 24 - hour intraocular pressure .
【學(xué)位授予單位】：華中科技大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2014
【分類號(hào)】：R775.2
【共引文獻(xiàn)】
相關(guān)期刊論文 前10條
1 William C Stewart;Jeanette A Stewart;Marko A Mychaskiw;;拉坦、曲伏及比馬前列素治療青光眼的成本效用分析(英文)[J];國際眼科雜志;2009年05期
2 趙軍梅;;固定聯(lián)合制劑拉坦前列素/噻嗎洛爾早晨與晚間應(yīng)用的比較[J];國際眼科雜志;2011年07期
3 李平余,盧清君;青光眼藥物治療的新趨勢—合理聯(lián)合用藥[J];國外醫(yī)學(xué)(眼科學(xué)分冊(cè));2004年01期
4 Haydar Erdogan;Ayse Vural Ozec;Cengiz Caner;Mustafa Ilker Toker;Mustafa Kemal Arici;Aysen Topalkara;;Effect of latanoprost/timolol and dorzolamide/tiomolol on intraocular pressure after phacoemulsification surgery[J];International Journal of Ophthalmology(English Edition);2011年02期
5 王婷;梁濤;喻文倩;劉珂鳳;;拉坦噻嗎滴眼液對(duì)玻璃體切割術(shù)后難治性青光眼的短期療效[J];國際眼科雜志;2013年09期
6 Achyut N Pandey;S Sujata;;Study of long term structural and functional changes in medically controlled glaucoma[J];International Journal of Ophthalmology(English Edition);2014年01期
7 Curt Hartleben-Matkin;Diddier Prada;Rafael Mancilla-Vences;;A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG[J];International Journal of Ophthalmology(English Edition);2014年02期
8 Murat Atabey Ozer;Mutlu Acar;Cem Yildirim;;Intraocular pressure-lowering effects of commonly used fixed combination drugs with timolol in the management of primary open angle glaucoma[J];International Journal of Ophthalmology;2014年05期
9 Yi Xing;Fa-Gang Jiang;Teng Li;;Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension:a systematic review and meta-analysis[J];International Journal of Ophthalmology;2014年05期
10 劉曉陽;王以朋;于斌;;后外側(cè)融合與后路椎體間融合治療腰椎滑脫的Meta分析[J];中國骨與關(guān)節(jié)雜志;2013年10期
相關(guān)博士學(xué)位論文 前7條
1 張震洪;他汀類藥物對(duì)尿蛋白、腎臟事件、非透析患者全因死亡的系統(tǒng)評(píng)價(jià)[D];南方醫(yī)科大學(xué);2014年
2 何國超;接骨板vs髓內(nèi)釘和髓內(nèi)釘vs外固定架固定治療成人脛骨干骨折的系統(tǒng)評(píng)價(jià)[D];南方醫(yī)科大學(xué);2014年
3 朱研;口服ω-3不飽和必須脂肪酸對(duì)青光眼治療后干眼的療效觀察[D];武漢大學(xué);2013年
4 朱y，
本文編號(hào)：2134525
本文鏈接：http://sikaile.net/yixuelunwen/yank/2134525.html
最近更新
教材專著
